Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Operating Expenses: 2009-2024

Historic Operating Expenses for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $81.1 million.

  • Anika Therapeutics' Operating Expenses fell 3.45% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 67.25%. This contributed to the annual value of $81.1 million for FY2024, which is 0.72% down from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Operating Expenses is $81.1 million, which was down 0.72% from $81.7 million recorded in FY2023.
  • Anika Therapeutics' Operating Expenses' 5-year high stood at $97.3 million during FY2020, with a 5-year trough of $69.5 million in FY2022.
  • In the last 3 years, Anika Therapeutics' Operating Expenses had a median value of $81.1 million in 2024 and averaged $77.4 million.
  • In the last 5 years, Anika Therapeutics' Operating Expenses spiked by 88.60% in 2020 and then fell by 17.48% in 2021.
  • Anika Therapeutics' Operating Expenses (Yearly) stood at $97.3 million in 2020, then decreased by 17.48% to $80.3 million in 2021, then decreased by 13.42% to $69.5 million in 2022, then grew by 17.45% to $81.7 million in 2023, then decreased by 0.72% to $81.1 million in 2024.